Education & GREAT Committee GREAT... · 19-Sep-2019 GCIG Session 21-Sep-2019. Education Committee...
Transcript of Education & GREAT Committee GREAT... · 19-Sep-2019 GCIG Session 21-Sep-2019. Education Committee...
Education & GREAT
Committee
May 28, 20208:00 am EDT
GCIG Spring Meeting
GCIG Spring Meeting
Education & GREAT Committee
Agenda
• Approval of Report Berek
• IGCS & ASGO Fujiwara
• CCRN McCormack
• ESGO Ray-Coquard
• Patient Advocacy Chavez-Blanco
• Young Investigators Poveda
• PARSGO Sehouli
• WHO & NCI Trimble
Education Committee
IGCS
Keiichi Fujiwara
IGCS 2019 Rio De Janeiro
GCIG/CCRN/BrGOG/LatainAmerica
Meeting
19-Sep-2019
GCIG Session
21-Sep-2019
Education Committee
ASGO
Keiichi Fujiwara
ASGO 2019 in Incheon,
South Korea
GCIG Session 12-Oct-2019
Keiichi Talked about GCIG
and CCRN
Yusuke talked about the importance of
Harmonization in GCIGNoriko discussed the importance of
Research Nurse
Education Committee
GREAT Initiative
GCIG/CCRN/IGCS
Mary and Ted at the Presidential Plenary
For Cervical Cancer Initiative
CCRN & COVID
5th annual symposium scheduled for Da
Nang 22-23 Feb 2020
According to the Official Letter No. 545/UBND-VHXH on
February 1, 2020 of the Danang People's Committee announced
about the prevention and control of acute respiratory infections
caused by new strains of Corona virus in festive activities. The
content is including the stopping all the festivals and the
symposiums
• 20 papers in IJGC in 2015
– Between 5 to 40 citations per year since 2015
• New proposal:
– Joint-venture with ESGO
• Co publication of the new version
→ Smartphone application
– Actions
• 2 batchs of 10 guidelines
• identification of the 2 co-coordinators by
guidelines
• To define a realistic agenda (2019 to 2021)
• To define rules of publications
Updated GCIG/ESGO guidelines
Isabelle Ray-Coquard & Jonathan
Ledermann
List of Coordinators and co
coordinators
Coordinator Group Co-Coordinator Group
Uterine carcinosarcoma Ketta Lorusso Y MITO Ronnie Shapira-Frommer ISGO
Uterine LMS Jae-Weon Kim Y KGOG Ana Oaknin GEICO
Sex cord tumour Isabelle Ray Coquard Y GINECO Philipp Harter AGO
Germ Cell tumour Nicoletta Colombo MaNGO Oleysa Solheim NSGO
Cancerized teratoma Ros Glasspool SGCTG Christian Marth A-AGO
Ovarian small cell carcinoma Clare Scott ANZGOG Patricia Pautier GINECO
Mucinous carcinoma Jonathan Ledermann Y NCRI Jubilee Brown GOG-F
Ovarian clear cell carcinoma Antonio Gonzales Y GEICO Keiichi Fujiwara GOTIC
Trophoblastic diseases Michael Seckl ISSTD Leon Massuger EORTC
Low grade serous carcinoma David Gershenson Y GOG-F Charlie Gourley SGCTG
1st Round 2018 - 2019
Already presented and validated in 2019 (GCIG meeting in June and
Oral presentation at ESGO meting in Athens)
Smartphone application is underway for
- SCT
- GCT
- Mucinous
- LGSC
- OCCC
- …
List of Coordinators and co
coordinators
Coordinator Group Co-Coordinator Group
Non Squamous Vulva & Vagina Malignancies C Marth Y Aus-AGO M Leito NRG/GOG
Clear Cell Carcinoma of the Uterine Corpus
and Cervix D Tan Y Singapore GOG M Mc Cormack NCRI
Carcinoid Tumors of the Ovary E Gomez Y GICOM C Zamagni MITO
Low grade endometrial stromal sarcoma F Amant Y EORTC/GCG L Ceppi MANGOHigh Grade Endometrial and undifferentiated
Sarcoma A Oza PMH-C P Pautier GINECO
Papillary serous carcinoma of uterusK Takehara
S Sagae Y JGOG B Monk GOG F
Adenosarcomas of uterus M Friedlander Y ANZGOG R Ambrust NOGGO
Glandular carcinoma of cervix M Plante Y CCTG J Liu Shangai GOG
Borderline Ovarian tumors P Harter Y AGO C Lok DGOG
Small Cell Carcinoma of the Cervix (SCCC) O Solheim Y NSGO D Cibula CEECOG
2nd Round 2019 -
2020
Tasks & Organisation
• Coordination of new GCIG/ESGO guidelines for rare
tumors
• 2 chairs + 8/12 experts from each groups (designed by
each group)
• 1 or 2 pathologist from different groups for each
guidelines
• 1 methodologist from ESGO (François Planchamp for
bibliography research and design)
Where we are by topics
0 50 100 150 200 250 300
Non Squamous Vulva & Vagina Malignancies
Clear Cell Carcinoma of the Uterine Corpus and Cervix
Carcinoid Tumors of the Ovary
Low grade endometrial stromal sarcoma
High Grade Endometrial and undifferentiated Sarcoma
Papillary serous carcinoma of uterus
Adenosarcomas of uterus
Glandular carcinoma of cervix
Borderline Ovarian tumors
Small Cell Carcinoma of the Cervix (SCCC)
Different topics and activity
1st draft Pathology review Circulating in the working group Under review
Tasks & Organisation
• Coordination of new GCIG/ESGO guidelines for rare tumors
• 2 chairs + 8/12 experts from each groups (designed by each group)
• 1 or 2 pathologist from different groups for each guidelines
• 1 methodologist from ESGO (François Planchamp for bibliography research
and design)
• Agenda 2nd round:
– To finalize the Initial draft during summer
– To circulate within all groups before October
– Final draft to be presented at the next GCIG meeting (Autumn 2020)
– Oral presentation in an International congress ? Where/When?
– Publication paper for all the guidelines?
Gynecologic Cancer InterGroup
Cervix Cancer Research Network
Best Practices for Patient Advocacy
and Clinical Trials
GCIG Harmonisation Committee
Update
ADRIANA CHÁVEZ-BLANCO,DVM.Gynecologic Cancer InterGroup
Cervix Cancer Research Network (GCIG CCRN)Co-ordinator, Latin América & CCRN Sites.
GCIG Education Committee, Spring Meeting May 28, 2020
Gynecologic Cancer InterGroup
Cervix Cancer Research Network
Best Practices for Patient Advocacy and Clinical Trials
A GCIG Harmonisation Committee Initiative
Objective:
✓ How (and if) GCIG groups involve patients into their activities
✓ Encourage advocacy groups to join their GCIG groups
✓ Creation of an Advisory Panel
✓ Development of Templates
GCIG Education Committee Spring Meeting May 28, 2020
Gynecologic Cancer InterGroup
Cervix Cancer Research Network
Best Practices for Patient Advocacy and Clinical Trials
(cont.)
❖ Survey
To provide feedback on the involvement of the patients of patients /
carers / patient advocates within each GCIG group
❖ Challenges
✓ funding,
✓ sustainability,
✓ proof of value,
✓ volunteers are sometimes very sick
GCIG Education Committee Spring Meeting May 28, 2020
Gynecologic Cancer InterGroup
Cervix Cancer Research Network
GCIG Education Committee Spring Meeting May 28, 2020
GCIG Spring Meeting
Mentoring Young Investigators
Andrés Poveda,MD
GCIG Past-Chair
GCIG Spring Meeting – May 28th 2020, Virtual Meeting
GCIG Spring Meeting
• This program is a mandate of the GCIG Strategic Planning meeting
2018.
Objective:
• to foster the involvement of more junior investigators with GCIG.
• Set the basis to start this program in the 2019 GCIG Autumn
meeting (Athens).
GCIG Spring Meeting – May 28th 2020, Virtual Meeting
GCIG Strategic PlannIng Meeting 2018.
SUMMARY
Definition of Young Investigators:
After discussion of the strategic planning meeting definition of “junior
investigator”, the Executive Committee agreed that, for these GCIG
purposes, a Junior Investigator is:
a) a trained medical, gynecologic, or radiation oncologist with a
defined primary focus in gynecologic cancers;
b) ideally within 10 years of completion of last training (clinical or
postdoctoral fellowship);
c) preliminarily experienced in phase 2/3 clinical trials in an active role
(study design, methodology, etc.), translational, or QoL/PRO
gynecologic cancer investigation.
d) an active member of a GCIG member group.
GCIG Fall Meeting – November 1st 2019, Athens
GCIG Strategic PlannIng Meeting 2018.
SUMMARY
Application in order to select the participants in this program:
• An application form to be sent to each GCIG group member, so
that each group can propose a candidate.
Proposals to be discussed:
• Consider groups creating their co-operative groups.
• Total number of participants to be set up (maximum 1 per GCIG group).
• Possibility to reserve a slot for competitive access to present at the
translational meeting based on the best abstract or abstracts.
• When new trials are discussed with industry, the inclusion of young
investigators in the group that performs the translational design, to be
negotiated.
GCIG Fall Meeting – November 1st 2019, Athens
GCIG Strategic PlannIng Meeting 2018.
SUMMARY
INVOLVEMENT
• Each member group should commit one of their 6 slots to a young
investigator each meeting.
• Each GCIG-badged study should have an identified young
investigator Co-PI.
• Mentorship of new groups should include identification of young
investigator(s) to participate in the mentoring process from the
outset.
GCIG Fall Meeting – November 1st 2019, Athens
GCIG Strategic PlannIng Meeting 2018.
SUMMARY
OPPORTUNITIES
• There should be a competitive process to identify young
investigator(s) for participation in Consensus and Brainstorming
conferences.
• Additional young investigators should be able to attend the GCIG
meetings through a competitive opportunity. GCIG will identify
additional observational “slots” for this participation. This opportunity
should have an “award” title for academic recognition, and be
funded (ideally; eg travel award sponsored by a GCIG pharma
member).
GCIG Fall Meeting – November 1st 2019, Athens
GCIG Strategic PlannIng Meeting 2018.
SUMMARY
OPPORTUNITIES
– A satellite session(s) targeted to the young investigators should be an
ongoing event.
– Teach key elements of trial design and execution: scientific
justification, design, statistics, PRO endpoints, data integrity,
international cooperation.
– Review of and assistance with ongoing trial design.
– Networking opportunities with GCIG member groups.
– Expansion into a one day trial design educational symposium at
next GCIG meeting (Athens, GCIG Autumn Meeting 2019 ).
GCIG Fall Meeting – May 2018, Chicago
GCIG Fall Meeting
SUMMARY
PROGRAM
GCIG Fall Meeting – November 1st 2019, Chicago
GCIG Fall Meeting
SUMMARY
ATTENDEES
- N: 16 YI + 5 Lecturers + 1 OPS
- REPRESENTED GROUPS:
- AGO-D, ASGO, BR-GOG, CEEGOG, GINECO, GOTIC, ISGOG, JGOG, KGOG,
KOLKATA-GOG, MANGO, MITO, SAKK, SGCTG, SGOG, Singapore-GCG.
- MAINLY LINKED TO PHASE-I AND TRASLATIONAL RESEARCH
– Networking opportunities with GCIG member groups.
– Expansion into a one day trial design educational symposium at
next GCIG meeting (CHICAGO, GCIG Spring Meeting 2020 ).
GCIG Fall Meeting – November 1st 2019, Athens
GCIG Fall Meeting
ACTIONS
- SURVEY/FEEDBACK FROM PARTICIPANTS
Feedback from the participants would be required.
– Has the first meeting of the YIP met your expectations?
– What do you expect as a result of participation in the full YI program?
– Please send us any suggestions that might help us to improve the program.
– SENT (by email) IN NOV 2019?
– NO ANSWERS
- Expansion into a one day trial design educational symposium
at next GCIG meeting (CHICAGO, GCIG Spring Meeting 2020 )
- CANCELLED.
GCIG Spring Meeting – May 28th 2020, Virtual Meeting
GCIG Spring Meeting
PLANNING MEETING BY TC FEB 27,2020
SUMMARY
• Review:
– The October 31, 2019 Athens Young Investigator Program agenda was
reviewed.
– The Statistical Considerations presentation did not happen in Athens so will need
to be considered in the future.
– We had planned to survey the attendees to determine their interest but this did
not happen.
– This first session was a fairly general overview for the GCIG Member Group
Young Investigator delegates.
GCIG Spring Meeting – May 28th 2020, Virtual Meeting
GCIG Spring Meeting
PLANNING MEETING BY TC FEB 27,2020
SUMMARY
• Plan for May 27, 2020 in Chicago:
– Attendees: many of the same YI delegates from GCIG Member Groups.
– Schedule: 2-3 hours at front end of meeting
– Curriculum Ideas:
– Start each session with a very brief overview – GCIG Mission and Vision – no more than 5 minutes
– Focus on clinical trial types pertinent to international collaboration and from the standpoint of investigator-initiated trials. Discuss good trial methodology (the gold standard) and discuss the components of trial design that can be problematic in the international setting.
• Suggest speakers.
GCIG Spring Meeting – May 28th 2020, Virtual Meeting
GCIG Spring Meeting
PLANNING MEETING BY TC FEB 27,2020
SUMMARY
• Plan for May 27, 2020 in Chicago:
– Design of control:• What constitutes a control?
• Understanding of why historical controls no longer valid.
– Primary and Secondary endpoints:
– Trial types
– Statistical considerations – Harm Stats Committee involvement?
– Challenges of rare tumour trials – Clare Scott/Isabelle Ray-Coquard• GCIG-ESGO Rare Tumor guidelines and smart phone app
GCIG Spring Meeting – May 28th 2020, Virtual Meeting
GCIG Spring Meeting
PLANNING MEETING BY TC FEB 27,2020
SUMMARY
• Plan for May 27, 2020 in Chicago:
• Presenters/presentations:– have speakers provide power point slides for distribution beforehand and that can stand
alone as a reference
– will look into cost and feasibility of taping presentations for reference
• Other:
– We will ask the GCIG-Foundation if we can offer to cover the cost of 1-night accommodation for the attendees to facilitate their earlier arrival to the GCIG Spring Meeting.
GCIG Spring Meeting – May 28th 2020, Virtual Meeting
GCIG Spring Meeting
PROPOSALS
PROPOSALS FOR THE NEXT MEETING
FALL 2020, Leuven? (TBD)
• Online lectures.
• Ask the groups to keep the same person.
• Eclectic group, some close to the Nobel prize, some new
in the field
• Mentor, keep in touch, and lead them.
• 2 years Program, follow up of progress of participants.
Mentorship
GCIG Spring Meeting – May 28th 2020, Virtual Meeting
WHO Global InitiativeUS
NCI
Global partnership
Update on global initiative:
1. Call for action by Dr. Tedros, May 2018
2. Resolution endorsed by WHO Executive Committee February
2020 and submitted to World Health Assembly May 2020;
encompasses primary prevention with HPV vaccination,
screening, treatment of precancer, treatment of invasive cancer,
palliative care, public education, strengthened data collection, and
expanded access to cancer services
3. No earmarked new money at WHO for the initiative; Clinton Health
Access Initiative (CHAI) has seconded a staff member to assist Dr.
Nono Simelela in her role as WHO coordinator for the initiative
4. WHO Geneva working with WHO regional offices on specific
countries (UN Joint Program 6, AFRO 8)
Update on global initiative:
II
US
NCI
Global partnership
Update II:
1. International Atomic Energy Agency (Vienna) responsible for
helping countries with national cancer control planning, as well as
implementation of components related to cancer imaging, nuclear
medicine, and radiation therapy, including training of radiation
oncologists, radiologists, nuclear medicine physicians, medical
physicists, nurses, and technicians; recently signed MOU with
UNAIDS for joint work on cervical cancer
2. UNAIDS responsible for helping countries address cervical cancer
control in HIV+ populations
3. WHO International Agency for Research on Cancer responsible for
helping countries with cancer registries; working with WHO
Geneva on links to death registries, increased use of unique
personal identifiers, and strengthened health surveillance
Update on global initiative:
III
US
NCI
Global partnership
Update III:
1. GAVI working on HPV vaccination in GAVI-eligible low-income
countries; WHO Pan-American Health Organization includes HPV
vaccines in its bulk-purchasing program for countries in the
Americas
2. US NCI and Gates Foundation funding definitive non-inferiority
phase III trial of one vs. two doses of Gardasil9® and Cervarix® in
Costa Rica
3. UNITAID working with CHAI and Expertise France to fund studies
of cervical cancer screening, triage, and treatment of pre-cancer in
subset of African and Central American countries
4. WHO Geneva working to develop educational materials for civil
society as well as evidence-based guidelines for screening, triage
and treatment of pre-cancer, treatment of invasive cancer,
symptom management, and palliative care
Update on global initiative:
IV
US
NCI
Global partnership
Research and education:
1. WHO Geneva has set up HPV and cervical cancer research
working group, co-chaired by Drs. Doug Lowy (US NCI), Maribel
Almonte (WHO IARC), and Nathalie Broutet (WHO Geneva); staff
support: Ted Trimble and Doug Perin (US NCI)
2. Current HPV and cervical cancer research grants and contracts
are largely supported by the US National Institutes of Health (50%
US NCI, 25% other NIH institutes)
3. Educational needs include training, mentoring, and continuing
education for all disciplines required for management of women
with precancer and invasive cervical cancer
4. Research needs include implementation science across cancer
continuum as well as improvements in resource-sparing treatment
and symptom management for women with invasive cervical
cancer
Proposed cervical cancer
learning network
US
NCI
Global partnership
Objectives:
1. Improve access to and quality of cancer treatment, symptom
management, and palliative care for women with invasive cervical
cancer
2. Link mentors with expertise in cervical cancer management at
cancer centers in high-income and high-upper-middle income
countries with clinicians treating women with invasive cervical cancer
at high-volume sites in low- and low-middle income countries
3. Build capacity for and conduct prospective clinical research,
including prospective cohort studies, clinical trials, and implementation
science, to improve care for women with invasive cervical cancer
Cervical cancer learning
network: II
US
NCI
Global partnership
Core components:
1. GCIG and GCIG Cervical Cancer Research Network
2. GCIG member groups
3. Cancer centers in high- and high-middle income countries
4. Medical professional societies
5. World Health Organization
6. International Atomic Energy Agency
7. Industry
8. Civil society
9. Other?
Cervical cancer learning
network: III
US
NCI
Global partnership
Potential funders:
1. Global health development agencies in high-income countries?
2. NGOs?
3. Medical professional societies (for travel of mentors and
fellows/junior investigators)
4. US National Institutes of Health?
5. Industry-associated foundations?
Education & GREAT Committee
Thank you!